Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses
Abstract
Morbidity and mortality resulting from influenza-like disease are a threat, especially for older adults. To improve case management, next-generation broad-spectrum antiviral therapeutics that are efficacious against major drivers of influenza-like disease, including influenza viruses and respiratory syncytial virus (RSV), are urgently needed.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Aug 01, 2018
- Source ID
- 10.1128/aac.00766-18
Entities
People
- Alexander A. Kolykhalov
- Alexander L. Greninger
- Anice C. Lowen
- Barbara Ludeke
- Deborah G. Mitchell
- George R. Painter
- Jasmina M. Luczo
- Jeong-Joong Yoon
- Ketaki Ganti
- Mark A. Lockwood
- Mart Toots
- Martin L. Moore
- Michael G. Natchus
- Myung-eun Lee
- Rachel Fearns
- Richard K Plemper
- Robert M. Cox
- Stephen M Tompkins
- Sujin Lee
- Vindya Edpuganti
- Zachary M Sticher
Organizations
- Boston University
- Children's Healthcare of Atlanta
- Defense Threat Reduction Agency
- Emory University
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- Georgia State University
- National Institute of Allergy and Infectious Diseases
- University of Georgia
- University of Washington